Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy
Not Applicable
Recruiting
- Conditions
- Polyp of ColonAdenoma ColonColorectal Cancer
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- NEC Corporation
- Target Recruit Count
- 830
- Registration Number
- NCT05611151
- Locations
- 🇺🇸
Kansas City VA Hospital, Kansas City, Missouri, United States
🇩🇪GastroZentrum Lippe, Bad Salzuflen, Germany
🇮🇹Humanitas Mater Domini, Castellanza, Italy
News
NEC and Chugai Pharmaceutical Develop AI System to Accelerate Cancer Drug Combination Discovery
NEC Corporation and Chugai Pharmaceutical have successfully tested an AI system that can predict effective cancer drug combinations, potentially reducing prediction time by approximately 50% compared to conventional methods.
NEC's Oral Cancer Vaccine NECVAX-NEO1 Shows Promise in Phase 1 Trial
NEC Bio Therapeutics' NECVAX-NEO1, combined with checkpoint inhibitors, demonstrates encouraging interim results in a Phase 1 trial for solid tumors.